Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginkgo biloba to prevent cisplatin-induced tinnitus and ototoxicity
IRCT2015020720982N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in tinnitus, ototoxicity and cisplatin-induced ototoxicity comparing Ginkgo biloba extract with Placebo (2 arms). Primary endpoints: Prevention of cisplatin-induced ototoxicity and Prevention of tinnitus. Started Nov 2015; status: completed.
02
Drugs
ginkgo biloba extract
03
Conditions
tinnitusototoxicitycisplatin-induced ototoxicity
Beyond the preview
Go deeper on IRCT2015020720982N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2015020720982N1.